Gilead Sciences, Inc.
NEWS
It’s no secret that China has become an ever-increasing important component for drug development. Not only is the country seen as a lucrative market for drugs, entities within the country are making heavy investments in the global biotech industry.
Ahead of next Monday’s U.S. Food and Drug Administration (FDA) committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis, concerns over blood clots, may scuttle the drug’s chances.
Less than one week after licensing three non-alcoholic steatohepatitis (NASH) programs from Eli Lilly, startup company Terns Pharmaceuticals has strengthened its leadership team with the appointment of two scientific advisors.
Investors in Ionis Pharmaceuticals are happy this morning after the company announced it struck another licensing deal with AstraZeneca that has the potential to yield up to $330 million.
When it comes to large-cap biotech companies, Gilead Sciences, Biogen and Celgene are always worth investment consideration, but are not without their risks.
The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.
If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
Days after being tapped to helm the U.S. Centers for Disease Control and Prevention, Dr. Robert Redfield predicted the AIDs epidemic can be defeated within the next three to seven years and the challenges of the opioid crisis can also be brought “to its knees.”
The U.S. Food and Drug Administration (FDA) approved Mylan NV’s Symfi (efavirnenz, lamivudine and tenofovir disoproxil fumarate) for adult and pediatric HIV-1 patients.This marks the third HIV approval for the company.
JOBS
IN THE PRESS